<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03101787</url>
  </required_header>
  <id_info>
    <org_study_id>NL58067.068.16</org_study_id>
    <nct_id>NCT03101787</nct_id>
  </id_info>
  <brief_title>Early Initiation of Extracorporeal Life Support in Refractory OHCA</brief_title>
  <acronym>INCEPTION</acronym>
  <official_title>Early Initiation of Extracorporeal Life Support in Refractory OHCA (INCEPTION)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nederlandse organisatie voor gezondheidsonderzoek en zorginnovatie (ZonMw)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Getinge Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Maastricht University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Despite adequate conventional cardiopulmonary resuscitation (CCPR) and attempted
      defibrillation, a considerable number of patients in cardiac arrest fail to achieve sustained
      return of spontaneous circulation. The INCEPTION trial is a multicenter, randomized
      controlled trial that will explore extracorporeal cardiopulmonary resuscitation (ECPR) in
      patients in refractory out-of-hospital cardiac arrest (OHCA) presenting with ventricular
      fibrillation or tachycardia. It aims to determine the effect on survival and neurological
      outcome. Additionally, it will evaluate the feasibility and cost-effectiveness of ECPR.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There are approximately 275,000 cases of out-of-hospital cardiac arrest (OHCA) per year in
      Europe, of which two-thirds have a primary cardiac origin. However, despite adequate
      conventional cardiopulmonary resuscitation (CCPR) and attempted defibrillation, a
      considerable number of these patients fail to achieve sustained return of spontaneous
      circulation (ROSC).

      Treatment of the underlying cause of the arrest, in most cases coronary artery occlusion, is
      paramount. But in the absence of ROSC, the possibilities to perform these life-saving
      interventions are limited. Continued CCPR is currently the standard of care for these
      patients. Initiation of extracorporeal cardiopulmonary resuscitation (ECPR) restores
      circulation, with the potential to minimize (or even reversing) organ damage, prevent
      re-arrest due to ischemia-triggered myocardial dysfunction and providing a bridge to possible
      diagnosis and treatment. Several studies have demonstrated that ECPR is feasible and may be
      advantageous with respect to survival and neurological outcome.

      The INCEPTION trial aims to compare ECPR to CCPR in the population that is expected to
      benefit the most from this intervention: young patients presenting with ventricular
      fibrillation or tachycardia (VF/VT) and a refractory cardiac arrest. Furthermore, it will
      provide data on the cost-effectiveness of this intervention, which to date has been
      unavailable. Although the costs may prove to be high, the gain in quality-adjusted life years
      (QALY's) may be substantial given the fact that most patients are relatively young and the
      current alternative carries a poor prognosis. This can determine whether ECPR should be
      pursued as a standard of care in patients with refractory arrest.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2017</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">May 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>30-day survival rate with favorable neurological status</measure>
    <time_frame>30 days</time_frame>
    <description>Favorable neurological status is defined as 1 or 3 on the using Cerebral Performance Category scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>QALY's</measure>
    <time_frame>3 months, 6 months and 1 year</time_frame>
    <description>Quality-adjusted-life-years using EQ-5D-5L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Costs of ECPR and CCPR</measure>
    <time_frame>3 months, 6 months and 1 year</time_frame>
    <description>Using the Case Report Form, Productivity Cost Questionnaire (iPCQ) and Medical Consumption Questionnaire (iMCQ)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival status at 3 months, 6 months and 1 year</measure>
    <time_frame>3 months, 6 months and 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurologic status at 3 months, 6 months and 1 year</measure>
    <time_frame>3 months, 6 months and 1 year</time_frame>
    <description>Favorable neurological status is defined as 1 or 3 on the using Cerebral Performance Category scale</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Cardiac Arrest</condition>
  <condition>Out-Of-Hospital Cardiac Arrest</condition>
  <condition>Sudden Cardiac Death</condition>
  <arm_group>
    <arm_group_label>CCPR protocol</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Preclinical Cardiopulmonary resuscitation (CPR) by emergency medical services (EMS) and rapid transport to the emergency department with ongoing mechanical CPR and advanced cardiac life support (ACLS).
Clinical Upon the patient's arrival, the standard of care (CCPR) will be continued according to ERC guidelines.
No special preparations for the trial are needed before the patient's arrival.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ECPR protocol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Preclinical Cardiopulmonary resuscitation (CPR) by emergency medical services (EMS) and transport to the emergency department with ongoing mechanical CPR and advanced cardiac life support (ACLS).
Clinical The ECPR team is mobilized while the patient is transported to the hospital. Initiation of extracorporeal cardiopulmonary resuscitation (ECPR).
Time from arrest to start of cannulation is &lt; 60 minutes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Extracorporeal cardiopulmonary resuscitation (ECPR)</intervention_name>
    <description>In addition to the routine response team, the ECLS team are called to the ED while the patient is transported to the hospital.
The team consists of a physician skilled and qualified in femoral cannulation, a perfusionist and a scrub nurse.
Upon the patient's arrival at the emergency department, CPR will be continued, with continuation of mechanical chest compressions with minimization of interruptions.
Time from arrest to start of cannulation is &lt; 60 minutes.</description>
    <arm_group_label>ECPR protocol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. ≥18 - ≤70 years

          2. Witnessed OHCA

          3. Initial rhythm of VF/VT or AED administered

          4. Bystander BLS

          5. No ROSC

        Exclusion Criteria:

          1. ROSC

          2. Terminal heart failure (NYHA III or IV)

          3. Severe pulmonary disease (COPD GIII of GIV)

          4. Oncological disease

          5. Pregnancy

          6. Bilateral femoral bypass surgery

          7. Pre-arrest CPC-score of 3 or 4

          8. Advanced directive

          9. Multitrauma (ISS &gt;15)

         10. Start cannulation &gt; 60 min after arrest
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marcel van de Poll, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maastricht UMC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Martje Suverein, MD</last_name>
    <phone>+31433874373</phone>
    <email>martje.suverein@mumc.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Maastricht UMC</name>
      <address>
        <city>Maastricht</city>
        <state>Limburg</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martje Suverein, MD</last_name>
      <phone>+3143 387 4373</phone>
      <email>martje.suverein@mumc.nl</email>
    </contact>
    <contact_backup>
      <last_name>Marcel van de Poll, MD, PhD</last_name>
      <email>marcel.vande.poll@mumc.nl</email>
    </contact_backup>
    <investigator>
      <last_name>Martine Bol, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thijs Delnoij, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Roberto Lorusso, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jos Maessen, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marcel van de Poll, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Paul Roekaerts, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Patrick Weerwind, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Catharina Ziekenhuis</name>
      <address>
        <city>Eindhoven</city>
        <state>Noord-Brabant</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ka Yan Lam, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Academisch Medisch Centrum</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord-Holland</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alexander Vlaar, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Isala Klinieken</name>
      <address>
        <city>Zwolle</city>
        <state>Overijssel</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>George Brandon Bravo Bruinsma, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Leids Universitair Medisch Centrum</name>
      <address>
        <city>Leiden</city>
        <state>Zuid-Holland</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carlos Elzo Kraemer, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitair Medisch Centrum Utrecht</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Joris van der Heijden, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 30, 2017</study_first_submitted>
  <study_first_submitted_qc>March 30, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 5, 2017</study_first_posted>
  <last_update_submitted>November 21, 2017</last_update_submitted>
  <last_update_submitted_qc>November 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ECPR</keyword>
  <keyword>Extracorporeal CardioPulmonary Resuscitation</keyword>
  <keyword>OHCA</keyword>
  <keyword>Out-of-Hospital Cardiac Arrest</keyword>
  <keyword>CPR</keyword>
  <keyword>CardioPulmonary Resuscitation</keyword>
  <keyword>ECMO</keyword>
  <keyword>ExtraCorporeal Membrane Oxygenation</keyword>
  <keyword>Refractory Cardiac Arrest</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Arrest</mesh_term>
    <mesh_term>Death</mesh_term>
    <mesh_term>Out-of-Hospital Cardiac Arrest</mesh_term>
    <mesh_term>Death, Sudden, Cardiac</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

